Starpharma Holdings Limited · ASX:SPL
Starpharma — Goldman Sachs Tenth Annual Emerging Companies Conference 2019
36 slides from Starpharma's conference presentation, Apr 3, 2019
Slide 1: Starpharma Investor Presentation to Goldman Sachs Conference (ASX announcement)
For personal use only Starpharma Investor Presentation to Goldman Sachs Conference Melbourne, Australia; 3 April 2019: Starpharma (ASX: SPL, OTCQX: SPHRY) will today present to institutional investors at the Goldman Sachs Tenth Annual Emerging Companies Conference in Sydney. The invitation-only Gold
Slide 2: Goldman Sachs Emerging Leaders Conference
For personal use only Starpharma Holdings ASX:SPL Goldman Sachs Emerging Leaders Conference Dr Jackie Fairley, CEO April 2019
Slide 3: Important notice and disclaimer
Important notice and disclaimer This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking For personal use only terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”,
Slide 4: Overview
For personal use only 1 Overview 2 VivaGel® Portfolio 3 DEP® Portfolio 4 Outlook & Further Opportunities 3
Slide 5: Deep portfolio of high-value global products
Starpharma has a deep portfolio of high- value global products with the potential For personal use only to significantly improve patient outcomes Starpharma is an ASX300 company with Market capitalisation ~A$350M a proven record of (as at 1-Apr) development & Issued shares 371.7M commercialisation i
Slide 6: Deep portfolio of high-value global products
Starpharma has a deep portfolio of high-value global products with the potential to significantly improve patient outcomes For personal use only VIVAGEL® PORTFOLIO DEP® DRUG DELIVERY PORTFOLIO VivaGel® BV Starpharma’s SUBMISSION proprietary GRANTED APPROVED APPROVED dendrimer platform World-leading
Slide 7: Starpharma's pipeline
Starpharma’s pipeline Product Indication Preclinical Clinical/Regulatory Commercial For personal use only VIVAGEL® BV Bacterial Vaginosis VIVAGEL® VIVAGEL® CONDOM Anti-viral condom SPL7013 OPHTHALMIC Viral conjunctivitis DEP® DOCETAXEL Oncology INTERNAL DEP® DEP® CABAZITAXEL Oncology DEP® IRINOTECAN
Slide 8: Starpharma is in a strong financial position
Starpharma is in a strong financial position For personal use only 1H FY2019 1H FY2018 FY 2018 FY 2017 Key Financial Data A$M A$M A$M A$M Total revenue and income 0.7 1.2 5.0* 3.6 Loss from continuing operations (7.3) (6.2) (10.3) (15.2) Profit/(loss) from discontinued - - - 23.4 Sale of operation A
Slide 9: VivaGel Portfolio
For personal use only 1 Overview 2 VivaGel® Portfolio 3 DEP® Portfolio 4 Outlook & Further Opportunities 8
Slide 10: VivaGel portfolio - innovative, late-stage global products
VivaGel® portfolio - innovative, late-stage global products For personal use only VivaGel® BV VivaGel® condom A breakthrough product for BV Treatment World’s first & only & Prevention of Recurrent BV anti-viral condom • Launched in Australia & • Approved in Australia and the EU Canada; Approved in •
Slide 11: VivaGel BV Global Commercialisation Plan
VivaGel® BV Global Commercialisation Plan VivaGel® BV has been licensed for over 160 countries For personal use only Global market estimated to be >US$750M for BV treatment & >US$1B annually for BV prevention Multiple launches in 2019 include Australia (April/May) & Europe Q2CY19 Additional
Slide 12: Australian launch of VivaGel BV
Australian launch of VivaGel® BV – April/May 2019 Fleurstat BVgel will be the only OTC product available in Australian For personal use only pharmacies for the treatment of BV Examples of Aspen’s materials below: • Several key wholesalers will receive VivaGel® BV stock this week • Aspen’s medical an
Slide 13: Bacterial Vaginosis is an area of significant unmet need
Bacterial Vaginosis (BV) is an area of significant unmet need with a large market opportunity For personal use only 50-60% have Large market 1 in 3 recurrent BV opportunity women in the BV Treatment: US will get BV US$750M (est) Prevention of recurrent BV: US$1B (est) BV is an area of significant un
Slide 14: VivaGel BV - a breakthrough product
VivaGel® BV - a breakthrough product for the most common vaginal infection worldwide For personal use only VivaGel® BV is a patented, non-antibiotic, rapidly acting gel with a novel mechanism of action Acts rapidly to Non-antibiotic Selective Local effect, not Suitable for resolve treatment – avoids
Slide 15: Positive patient experiences from women who benefited
Positive patient experiences from women who have already benefited from VivaGel® BV For personal use only “VivaGel® BV is a wonderful product which specifically targets BV bacteria. My patients have called it a ‘life changing and miraculous treatment’.” - Dr Belvia Carter, Principal Investigator & O
Slide 16: Positive independent market research for VivaGel BV
Positive independent market research for VivaGel® BV - from US physicians and payers alike For personal use only US physicians estimate >70% of BV patients are interested in a non-antibiotic BV therapy “I would love to try it [VivaGel® BV] “It [VivaGel® BV] is certainly simple enough because it is n
Slide 17: VivaGel condom approved in Japan
VivaGel® condom approved in Japan – launch planned 2QCY19 For personal use only Okamoto Industries has total revenues of >US$1.1B and is Japan’s leading marketer of condoms with a majority share of the Japanese condom market • The VivaGel® condom received final regulatory approval in January 2019 al
Slide 18: DEP Portfolio
For personal use only 1 Overview 2 VivaGel® Portfolio 3 DEP® Portfolio 4 Outlook & Further Opportunities 17
Slide 19: DEP drug delivery platform enhances value of drugs
Starpharma’s DEP® drug delivery platform enhances the commercial and therapeutic value of a wide range of drugs For personal use only Improved Reduced efficacy1: DEP® side-effects1: DEP® reduces improves anti-cancer important side effects such as efficacy through better bone marrow toxicity / low wh
Slide 20: DEP platform enhances commercial and therapeutic value
Starpharma’s DEP® platform enhances the commercial and therapeutic value of a wide range of drugs For personal use only DEP® BENEFITS Improved Efficacy Reproducible results with many candidates & tumour types Improved Safety Reduced neutropenia/bone marrow toxicities Targeting Tumour Tissue 45-70 x
Slide 21: DEP platform enabled deep pipeline of internal products
Starpharma’s DEP® platform has enabled the creation of a deep pipeline of high-value internal products For personal use only DEP® docetaxel: Improved Efficacy Starpharma’s most Benefit in combination with marketed anti-cancer therapies advanced DEP® product - a Improved Safety detergent-free,
Slide 22: DEP docetaxel is an enhanced version of Taxotere
DEP® docetaxel is an enhanced version of widely used cancer drug, Taxotere® For personal use only Enhanced version of docetaxel (Taxotere®) - one of the most PHASE 1 RESULTS widely used cancer drugs for a • No steroid pre-treatment required due to DEP® range of tumours including docetaxel’s detergen
Slide 23: DEP docetaxel phase 2 program underway
DEP® docetaxel phase 2 program underway For personal use only PHASE 2 Positive interim results: (currently recruiting) Monotherapy arm • Trial results continue to show encouraging Multi-site trial – 4 sites efficacy signals (stable disease & tumour Commercial shrinkage); >70% of initial cohort now c
Slide 24: DEP docetaxel & cabazitaxel outperformed gemcitabine & Abraxane
DEP® docetaxel & DEP® cabazitaxel outperformed both gemcitabine & Abraxane® in human pancreatic cancer model For personal use only L e a d in g p a n c r e a tic c a n c e r th e r a p ie s s h o w m in im a l a c tiv ity ) 1400 3 M e a n T u m o u r V o lu m e (m m V e h ic le 1200 G e m c ita b in
Slide 25: DEP cabazitaxel is an enhanced version of Jevtana
DEP® cabazitaxel is an enhanced version of leading prostate cancer drug, Jevtana® For personal use only Starpharma’s patented DEP® cabazitaxel is an enhanced version of cabazitaxel (Jevtana®) – primarily used for prostate cancer and in clinical development for other cancers including breast and blad
Slide 26: DEP cabazitaxel phase 1/2 trial program underway
DEP® cabazitaxel phase 1 / 2 trial program underway Positive interim results: For personal use only PHASE 1 / 2 (currently recruiting) Phase 1: Open-label dose-escalation - currently recruiting Multi-site trial – currently • Several patients have been dosed with recruiting at Guy’s Hospital multiple
Slide 27: DEP irinotecan: enhanced version of irinotecan
DEP® irinotecan: an enhanced version of widely used anti-cancer drug irinotecan (Camptosar®) For personal use only DEP® irinotecan: advanced preparations for phase 1 / 2 trial underway, expected to commence in FY19 Irinotecan is a successful oncology agent – DEP® irinotecan incorporates the Camptosa
Slide 28: DEP irinotecan outperformed standard treatments in pancreatic model
DEP® irinotecan outperformed standard treatments in human pancreatic cancer model For personal use only DEP® irinotecan alone showed complete tumour regression and 100% survival in a human pancreatic cancer model Unlike DEP® irinotecan, conventional irinotecan +/- 5-FU showed minimal activity in thi
Slide 29: DEP irinotecan outperformed irinotecan in colon cancer models
DEP® irinotecan outperformed irinotecan (Camptosar®) in multiple human colon cancer models For personal use only DEP® irinotecan demonstrated significantly better anti-tumour activity and increased survival compared with irinotecan (Camptosar®) in multiple human colon cancer models HT-29 (colon) Xen
Slide 30: AstraZeneca's DEP programs illustrate potential returns
DEP® AstraZeneca’s DEP® programs illustrate the potential returns from DEP® partnered programs For personal use only Partnered-DEP® AstraZeneca has three active DEP® programs Starpharma produces DEP® candidates under research collaboration Partner selects candidate – either novel or existing drug (f
Slide 31: AstraZeneca's deal with Daiichi Sankyo illustrates value of ADCs
DEP® AstraZeneca’s recent deal with Daiichi Sankyo illustrates the value of ADCs For personal use only Starpharma has two Targeted DEP® (ADC) partnerships with “Global pharma giant AstraZeneca strikes world leading antibody-drug $6.9 billion deal to expand cancer portfolio” conjugate companies • In
Slide 32: Outlook & Further Opportunities
For personal use only 1 Overview 2 VivaGel® Portfolio 3 DEP® Portfolio 4 Outlook & Further Opportunities 31
Slide 33: Dendrimer platform yields opportunities - Radiopharmaceuticals
Starpharma’s dendrimer platform continues to yield valuable opportunities - Radiopharmaceuticals For personal use only Radiopharmaceuticals • Growing category with current sales ~$750M, & est. $12–15B by 20301 • Recent deals incl. Sirtex acquisition ~A$1.9B by CDH Investments DEP® Radiotherapeutic D
Slide 34: Platform generates multiple potential revenue streams
Starpharma’s platform generates multiple potential revenue streams & valuable partnering opportunities For personal use only PARTNERED LATE- STAGE PRODUCTS VivaGel® BV licensed around the world PARTNERED LATE- VivaGel® condom licensed broadly and launched STAGE PRODUCTS in Australia and Canada (& Ja
Slide 35: Outlook
Outlook For personal use only VIVAGEL® DEP® PORTFOLIO PORTFOLIO Progress with DEP® docetaxel & Launch of VivaGel® BV in Europe, DEP® cabazitaxel clinical trials Australia & other international markets DEP® irinotecan trial commencement – Meeting with FDA to address request for possible combination s
Slide 36: www.starpharma.com
For personal use only www.starpharma.com
Starpharma Holdings — Goldman Sachs Tenth Annual Emerging Companies Conference 2019 on 6ix